About this trial
This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
ECOG performance status score of 0 to 2.
Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.
Clinical stage cT0-2N0M0.
Underwent breast-conserving surgery.
Disqualifiers
Regional lymph node metastasis.
Distant metastasis.
Bilateral breast cancer.
Prior thoracic radiotherapy.
Trial design
Factorial
Treatments tested in this trial
Whole-breast irradiation and tumor bed boost
RadiationWhole-breast irradiation: 36 Gy in 15 fractions; Tumor bed boost: 48 Gy in 15 fractions
Partial-breast irradiation
RadiationPartial-breast irradiation: 40.05 Gy in 15 fractions or 26 Gy in 5 fractions
Treatment groups
Trial outcomes
Primary outcomes
Local recurrence rate
Ipsilateral breast recurrence rate
Secondary outcomes
Disease-free survival rate
Disease-free survival rate
Radiation-related adverse events
Adverse events
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: